HKSE:3613
Beijing Tong Ren Tang Chinese Medicine Company Limited · HKSE · Healthcare · HKD · FY for 2025
Figures on this page computed 2026-11-08 07:38 UTC
Last close
n/aHKD
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
12.3xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2025
18.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
26.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
54.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.03Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
6.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Growth is the furthest below its sector's middle: 0.25 against 0.47 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.04x
Its own average over 10 years, 1.45B.
- Profit0.75x
Its own average over 10 years, 528.1M.
- Free cash flow1.93x
Its own average over 10 years, 429.4M.
- Debt1.54x
Its own average over 10 years, 82.2M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 1.93 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 116.8 | 116.6 | 100.0 |
| 2018-12-31 | 139.6 | 138.2 | 100.0 |
| 2019-12-31 | 132.1 | 132.3 | 100.0 |
| 2020-12-31 | 121.3 | 129.1 | 100.0 |
| 2021-12-31 | 143.5 | 144.6 | 100.0 |
| 2022-12-31 | 159.7 | 153.7 | 100.0 |
| 2023-12-31 | 140.6 | 128.6 | 100.0 |
| 2024-12-31 | 148.6 | 119.0 | 100.0 |
| 2025-12-31 | 139.6 | 94.5 | 100.0 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- HKD
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- HKD
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- HKD
Figures behind the shape
Growth
2.8%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate2.8%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Five-year EPS growth rate-6.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
One-year change in net income-20.6%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Returns on capital
18.7%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital18.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity9.5%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets8.5%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
61.2%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin61.2%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin31.2%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin26.3%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin54.6%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
12.3xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings12.3x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2025
Price to book1.2x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA4.8x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio3.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.03safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.03
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio19.65
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage83.4x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score12.59
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
6.1%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield6.1%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Payout ratio73.8%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio2.8x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- HKD
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.